Value of plasma SN-38 levels and DPD activity in irinotecan-based individualized chemotherapy for advanced colorectal cancer with heterozygous type UGT1A1*6 or UGT1A1*28

References

• DeekenJFFiggWDBatesSESparreboomAToward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogeneticsAnticancer Drugs200718211112617159598
   PubMed Web of Science ®Google Scholar
• LeeWLockhartACKimRBRothenbergMLCancer pharmacogenomics: powerful tools in cancer chemotherapy and drug developmentOncologist200510210411115709212
   PubMed Web of Science ®Google Scholar
• OnoueMTeradaTKobayashiMUGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patientsCancer Chemother Pharmacol2014142136142
   Google Scholar
• HuZYYuQPeiQGuoCDose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase riskClin Cancer Res201016153832384220562211
   PubMed Web of Science ®Google Scholar
• JadaSRLimRWongCIRole of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patientsCancer Sci20079891461146717627617
   PubMed Web of Science ®Google Scholar
• WangYXuJMShenLPolymorphisms of UGT1A gene and irinotecan toxicity in Chinese colorectal cancer patientsZhonghua Zhong Liu Za Zhi20072912913916 Chinese18478930
   PubMedGoogle Scholar
• PatelJNPapachristosAPersonalizing chemotherapy dosing using pharmacological methodsCancer Chemother Pharmacol201576587989626298089
   PubMed Web of Science ®Google Scholar
• InnocentiFSchilskyRLRamírezJDose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancerJ Clin Oncol201432222328233424958824
   PubMed Web of Science ®Google Scholar
• ToffoliGSharmaMRMarangonEGenotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancerClin Cancer Res201723491892427507617
   PubMed Web of Science ®Google Scholar
• CaiXCaoWDingHAnalysis of UGT1A1*28 genotype and SN-38 pharmacokinetics for irinotecan-based chemotherapy in patients with advanced colorectal cancer: results from a multicenter, retrospective study in ShanghaiJ Cancer Res Clin Oncol201313991579158923892411
   PubMed Web of Science ®Google Scholar
• CaiXTianCWangLCorrelative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapyCancer Biol Ther201718318619328278081
   PubMed Web of Science ®Google Scholar
• MaringJGvan KuilenburgABHaasjesJReduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD geneBr J Cancer20028671028103311953843
   PubMed Web of Science ®Google Scholar
• FalvellaFSCheliSMartinettiADPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanBr J Clin Pharmacol201580358158825782327
   PubMed Web of Science ®Google Scholar
• SchmollHJVan CutsemESteinAESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision makingAnn Oncol201223102479251623012255
   PubMed Web of Science ®Google Scholar
• WatanabeTItabashiMShimadaYJapanese Society for Cancer of the Colon and RectumJapanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancerInt J Clin Oncol201520220723925782566
   PubMed Web of Science ®Google Scholar
• SatohTUraTYamadaYGenotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphismsCancer Sci2011102101868187321740478
   PubMed Web of Science ®Google Scholar
• LiuXChengDKuangQLiuGXuWAssociation between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in CaucasiansPLoS One201383e5848923516488
   PubMed Web of Science ®Google Scholar
• DiasMMPignonJPKarapetisCSThe effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysisPharmacogenomics J201414542443124709690
   PubMed Web of Science ®Google Scholar
• TakanoMSugiyamaT2UGT1A1 polymorphisms in cancer: impact on irinotecan treatmentPharmgenomics Pers Med201710616828280378
   PubMed Web of Science ®Google Scholar
• IchikawaWArakiKFujitaKRe: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose mattersJ Natl Cancer Inst20081003224225 author reply 22518230796
   PubMedGoogle Scholar
• ZhangAXingQQinSIntra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populationsPharmacogenomics J20077533333817060921
   PubMed Web of Science ®Google Scholar
• SumiyoshiHFujiwaraYOhuneTYamaokaNTamuraKYamakidoMHigh-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasmaJ Chromatogr B Biomed Appl199567023093168548021
   PubMedGoogle Scholar
• KimKPHongYSLeeJLA phase I study of UGT1A1 *28/*6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRIOncology201588316417225427841
   PubMed Web of Science ®Google Scholar
• DucreuxMYchouMSeitzJFIrinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): a clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancerJ Clin Oncol19991792901290810561369
   PubMed Web of Science ®Google Scholar
• MathijssenRHMarshSKarlssonMOIrinotecan pathway genotype analysis to predict pharmacokineticsClin Cancer Res200315993246325312960109
   PubMed Web of Science ®Google Scholar
• SaiKKaniwaNItodaMHaplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecanPharmacogenetics2003131274175714646693
   PubMedGoogle Scholar
• KitamuraYKusuharaHSugiyamaYFunctional characterization of multidrug resistance-associated protein 3 (mrp3/abcc3) in the basolateral efflux of glucuronide conjugates in the mouse small intestineJ Pharmacol Exp Ther2010332265966619889793
   PubMed Web of Science ®Google Scholar
• IusufDvan de SteegESchinkelAHHepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxificationClin Pharmacol Ther201292555956223010652
   PubMed Web of Science ®Google Scholar
• TeftWAWelchSLenehanJOATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapyBr J Cancer2015112585786525611302
   PubMed Web of Science ®Google Scholar
• PhelpsMASparreboomAIrinotecan pharmacogenetics: a finished puzzle?J Clin Oncol201432222287228924958823
   PubMed Web of Science ®Google Scholar
• SchaafLJHammondLATippingSJPhase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunctionClin Cancer Res200612123782379116778106
   PubMed Web of Science ®Google Scholar
• FujitaKSunakawaYMiwaKDelayed elimination of SN-38 in cancer patients with severe renal failureDrug Metab Dispos201139216116420980446
   PubMed Web of Science ®Google Scholar